Insmed Incorporated (INSM) Earnings — Revenue, EPS & EBITDA | Market Terminal

Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Get Full Access To Market Terminal For Free

Get Full Access To Market Terminal For Free

Insmed Incorporated (INSM)

Explore More Tools

Get Full Access To
Market Terminal For Free

Get Full Access To
Market Terminal For Free